Gw Pharmaceuticals Ipo Date

Gw pharmaceuticals ipo date

GW Pharmaceuticals PLC

GW Pharmaceuticals is a British biopharmaceutical company known for its multiple sclerosis treatment product nabiximols (brand name, Sativex) which was the first natural cannabis plant derivative to gain market approval in any country.[4] Another cannabis-based product, Epidiolex, was approved for treatment of epilepsy by the US Food and Drug Administration in 2018.[5]


GW Pharmaceuticals was founded in 1998 by Doctors Geoffrey Guy and Brian Whittle.

That year, they obtained a cultivation license from the United Kingdom Home Office and the MHRA, allowing the company to cultivate, possess and supply cannabis to conduct scientific research concerning medicinal uses of the plant.[6][7]

Later that year, GW Pharmaceuticals entered into a contract with HortaPharm B.V., a cannabis research and development corporation based in Amsterdam.[8] The company was founded by two expert horticulturists from California,[9]Robert Connell Clarke[10] and David Paul Watson, and grew and developed specialized strains of cannabis with permission from the Dutch government.[11][12][13][14]

In 2001, GW Pharmaceuticals listed on AIM, the junior market of the London Stock Exchange.[15] In May 2013, the company became dual-listed on the NASDAQ and AIM.[16]

Marketed products[edit]


Main article: Nabiximols

Nabiximols (trade name Sativex) is a botanical drug that is a cannabis extract, administered as a mouth spray; it was approved in the UK in 2010 as a treatment for multiple sclerosis (MS) patients to alleviate neuropathic pain, spasticity, overactive bladder, and other symptoms.[17]

Nabiximols is made with two unknown Cannabis strains, and is extracted with ethanol and carbon dioxide.[18][19]

In 2011, GW Pharmaceuticals concluded a partnership with Bayer for the distribution of Sativex in the UK,[20] and have an estimated annual production of 100 tons of medicinal cannabis since 2012.[21]

Products in development[edit]

Cannabidiol oral solution[edit]

In 2015 GW Pharmaceutical initiated Phase 3 clinical trials of cannabidiol by mouth for treatment of two orphan conditions in children – Dravet and Lennox-Gastaut syndromes.[22][23] GW also received fast track designation from the US FDA for use of the drug candidate to treat newborns with epilepsy.[24]

The drug, under the brandname Epidiolex, was given US FDA approval in June 2018.[25][26]

See also[edit]


  1. ^"GW Pharmaceuticals Ltd".

    17 August 2017.

  2. ^ The Observer, Sunday 17 April 2011)
  3. ^"Prices and markets Stocks of GW PHARM". 28 June 2001.

    Archived from the original on 15 May 2016. Retrieved 18 July 2012.

  4. ^Elizabeth Landau (21 June 2010). "World's first fully approved cannabis drug on sale in UK".
  5. ^Debra Goldschmidt and Susan Scutti.

    "FDA approves first cannabis-based drug". CNN. Retrieved 7 August 2019.

  6. ^Pete Brady (25 April 2003).

    Trade amc movie e-tickets for bitcoin

    "GW Pharm responds to CC". Archived from the original on 12 November 2013.

  7. ^Mary Lynn Mathre, R. N. (July 1997). Cannabis in Medical Practice: A Legal, Historical, and Pharmacological Overview of the Therapeutic Use of Marijuana (Google eBook).

    ISBN  – via Google Books.

  8. ^"The Inheritance of Chemical Phenotype in Cannabis sativa L.(HortaPharm B.V., 1075 VS, Amsterdam, The Netherlands and Instituto Sperimentale per le Colture Industriali, 40128 Bologna, Italy)". 1 January 2003.

  9. ^"sam-the-skunkman [Four Twenty Wiki]".

    Recent Press Releases 16 August 2011.

  10. ^"inauthor:"Robert Connell Clarke" – Google Search".
  11. ^Marks, MD; Tian, L; Wenger, JP; et al. (2009). "Seeds from the marijuana cultivar Skunk no.

    GW Pharmaceuticals

    1 were provided by HortaPharm BV (Amsterdam, The Netherlands) and imported under a US Drug Enforcement Administration (DEA) permit to a registered controlled substance research facility". J. Exp. Bot. 60 (13): 3715–26.

    GW Pharmaceuticals market stock research📈, should we buy $GWPH?

    doi:10.1093/jxb/erp210. PMC 2736886. PMID 19581347.

  12. ^"Details released of collaboration between GW Pharmaceuticals and HortaPharm medicinal cannabis".
  13. ^Breen, Bill (1 February 2004).

    "The Cannabis Conundrum".

    Gw pharmaceuticals ipo date

  14. ^Breen, Bill (1 February 2004). "Dr. Dope's Connection".
  15. ^"GW Pharma aims for $150m in Nasdaq offering".

    Gw pharmaceuticals ipo date

    Financial Times. Retrieved 6 July 2018.

  16. ^"UK Cannabis Grower on a High With Wall Street Funding Bid". International Business Times UK. 21 December 2013.

    Retrieved 23 August 2019.

  17. ^UK Medicines Online Nabiximols[permanent dead link] Page accessed 3 February 2016
  18. ^"Extraction of pharmaceutically active components from plant materials".

    Welcome to the Investor Relations section of the GW Pharmaceuticals website. Archived from the original on 6 October 2012. Retrieved 18 July 2012.

  19. ^"Is Big Pharma set to corner the American market on medical marijuana?". 25 April 2011.

    Archived from the original on 22 July 2012.

  20. ^"GWPharma – GW and Bayer Announce Marketing Agreement on Pioneering New Cannabis-based Treatment".

    Investor Relations 30 September 2004. Archived from the original on 21 October 2016. Retrieved 18 July 2012.

  21. ^"Medical Cannabis Strains – Geoffrey Guy, MD (GW Pharmaceuticals, UK (Conference)". 23 February 2010.
  22. ^Ward, Andrew (9 January 2014).

    Navigation menu

    "GW raises nearly $90m to develop childhood epilepsy treatment". Financial Times. Retrieved 20 January 2014.

  23. ^Butticè, Claudio (9 December 2015).

    Gw pharmaceuticals ipo date

    "Therapeutic Cannabis for children – a possible new treatment for epilepsy". Meds News.

    The best technique for exploring design options is

    Retrieved 3 February 2016.

  24. ^Tony Quested for Business Weekly. 6 August 2015 FDA backs cannabis-based medicine for in-danger newborns
  25. ^"FDA approves country's first medicine made from marijuana - STAT". STAT.

    Gw pharmaceuticals ipo date

    25 June 2018. Retrieved 25 June 2018.

  26. ^Julia Kollewe (25 June 2018), "UK epilepsy drug to become first cannabis-based medicine in US", The Guardian

External links[edit]